<DOC>
	<DOCNO>NCT00928785</DOCNO>
	<brief_summary>The purpose study demonstrate combine adult Tdap-IPV vaccine ( REPEVAX® ) provide similar rapid antibody response tetanus toxoid tetanus toxoid vaccine alone healthy adult .</brief_summary>
	<brief_title>Study Comparing Tdap-IPV Combined Vaccine With Tetanus Monovalent Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult age ≥18 year Last booster Tcontaining vaccine receive 5 10 year prior administration study vaccine ( document write evidence ) Subject vaccination history primary immunisation tetanus , diphtheria poliomyelitis contain vaccine recommend local vaccination calendar Negative urine pregnancy test female subject childbearing potential . A female subject reproductive potential must agree remain abstinent use ( partner use ) acceptable method birth control study period Subject sign informed consent form prior participation study Acute severe illness fever ( &gt; =38.0°C ) within last 3 day Hypersensitivity know allergy one component one study vaccine ( include formaldehyde , streptomycin , neomycin , polymyxin B , glutaraldehyde ) Anaphylactic allergic reaction previous dose vaccine contain diphtheria tetanus toxoid poliomyelitis virus pertussis ( acellular whole cell ) Guillain Barré syndrome neuropathy brachial plexus follow previous vaccination tetanus toxoid contain vaccine Known encephalopathy receipt pertussis vaccine neurological disorder injection antigens Progressive unstable neurological disorder , uncontrolled seizure progressive encephalopathy stabilize Known malignant disease , note : subject prostate breast cancer chemotherapeutic drug ( hormone block drug ) , subject skin cancer receive radiation therapy chemotherapy , subject history malignancy diseasefree least 5 year eligible enrollment Immunosuppressive therapy : High dose ( ≥ 20 mg/day prednisone equivalent ) systemic ( ≥ 14 day ) corticosteroid treatment daily alternate day within last 28 day ( inhaled corticosteroid allow ) Chemotherapeutic agent use treat cancer condition Treatments associate organ bone marrow transplantation Immune dysfunction cause medical condition , cause ( e.g. , congenital immunodeficiency , human immunodeficiency virus ( HIV ) infection , organ bone marrow transplantation , leukemia , lymphoma , Hodgkin 's disease , multiple myeloma generalize malignancy ) Known severe thrombocytopenia coagulation disorder contraindicate intramuscular injection Administration blood product include immunoglobulin within last 90 day plan Visit 3 Recent administration live vaccine ( ≤28 day ) inactivate vaccine ( ≤14 day ) vaccination plan Visit 3 For female subject , pregnancy ( positive pregnancy test first blood sample ) breastfeed Visit 3 Planned participation another clinical study present study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Tetanus Vaccine</keyword>
	<keyword>Tdap-IPV vaccine</keyword>
</DOC>